The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Kaio-Dia Europe
Toulouse, France
1-10 Employees
2021
Kaio-Dia was founded by and for Kaio Kim, who himself has type 1 diabetes. We manufacture our products under working conditions that we would like to have ourselves. Kaio-Dia products support a wide range of devices including Freestyle Libre, Dexcom, Guardian, Medtronic Simplera, Medtrum, GlucoMen Day, Eversense, Sibionics, Omnipod and many more ensuring you find the perfect fit for your device. We believe in sustainable and quality products, which is why we work with UWear. Everything we do reflects this way of thinking, from production to the final product. Here you can see where our products are manufactured:. We want to offer products that make life easier and better for the people who make them and for those who wear them. Kaio Dia products are therefore manufactured under fair working conditions and with the lowest possible impact on the environment.
Product
Horizontal Insulin Pump Pocket - Dia-Insulin Pump Case
... the Cool-Pack Gel to keep your insulin at the right temperature. ...
Wanders Engineering EDV Seminare Qualitätsmanagement EDV-Schulung
Leinfelden-Echterdingen, Germany
1-10 Employees
-
Join for access to sample ordering, device training, educational materials, product information, personalized resource updates, and more. Novo Nordisk is committed to responsible semaglutide use. Connect with organizations that provide in-depth obesity information and educational opportunities. NovoCare® provides affordability and access support resources to help your eligible patients obtain the medicine that’s right for them.
Product
The Tresiba® (insulin degludec) molecule is different by design
... insulin, has a longer half-life than insulin glargine1,7,8,9, ...
PharmaSens
Reinach, Switzerland
11-50 Employees
2006
We at PharmaSens are devoted to simplifying diabetes management. We are passionate about technology bringing more people with diabetes towards better treatment and a life with increased freedom. We are a privately held Swiss company, located in Biel. We are PharmaSens – A devoted group of people aiming to simplify diabetes management and making insulin pump therapy accessible for more people with diabetes. We at PharmaSens are devoted to changing this. We are developing a portfolio of three insulin patch pumps to bring more people towards better treatment and a life with increased freedom. PharmaSens submitted in December an application for a 510(k) clearance of the ‘niia essential’ groundbreaking insulin patch pump system. Please see “PharmaSens News” page for more information.
Product
Our niia insulin patch pumps
... PharmaSens Products | Our insulin patch ...
Fada Medical
Galway, Ireland
1-10 Employees
2022
We are developing a novel drug diffusion technology to increase the wear time and performance of a cannula to support consistent long term insulin pump use for people with type 1 diabetes. For people with type 1 diabetes, getting life saving insulin into their body is a lot of work. Fada Medical's mission is to optimize chronic drug therapy, making life easier for the people who need it. Starting with insulin delivery for those with type 1 diabetes, Fada Medical are developing diffusion technologies to prevent and negate the causes of early infusion set failure and cannula occlusion that make insulin therapy more difficult.
Core business
Longer duration insulin delivery
... to improve the delivery of insulin for people with Type 1 ...
Novo Nordisk Pharmatech A/S
Køge, Denmark
251-500 Employees
1949
We are committed to providing sustainable pharmaceutical materials through innovative and customised solutions. We are pleased to announce our attendance at the upcoming BPI Europe congress, taking place April 9-12 in Vienna. Novo Nordisk Pharmatech A/S is a pharmaceutical company and was established in 1949 as FeF Chemicals. Novo Nordisk Pharmatech A/S is the leading worldwide supplier of products as recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the biopharmaceutical and pharmaceutical industries. We improve biopharmaceutical manufacturing by developing and supplying innovative products used in the manufacturing of biopharmaceuticals. We as a company has attracted the leading pharmaceutical companies through our high product quality, extensive manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy. You can be sure you get the same high quality product, time after time, reliably delivered through local distribution networks. Our comprehensive documentation package and tailored support, which continues through the whole product life cycle, gives you total peace of mind.
Product
The Insulin peptide family
... Insulin is only one member of a family of peptide hormones and growth ...
Mercodia AB
Uppsala, Sweden
51-100 Employees
1991
Mercodia develops tools to advance life science and pharmaceutical research. We are committed to delivering products and services with the highest reliability and accuracy, becoming a trusted and valued partner to customers worldwide. Our vision is to improve human health through the use of our products and services by scientists worldwide. Mercodia was founded 1991 in Uppsala by Erling Holmlund, a chemist and entrepreneur from northern Sweden. We are proud of our strong company culture. We are delighted to announce that effective January 1, 2024, we have established a new distribution partnership in Spain with Concile Diagnostics S.L. Mercodia will offer customers products and services with well-defined quality and high precision of delivery. Mercodia operates in compliance with the principles of Good Laboratory Practice (GLP) as established by the OECD and the European Community at the time of the inspection.
Product
Insulin ELISA - Mercodia
... Insulin ELISA - ...
Diabetic Outlet
-
1-10 Employees
-
The HTN Advanced B-Complex is the first high-potency vitamin B-complex available in convenient sustained-release caplets.
Product
EasyTouch Insulin Syringes U-100
... EasyTouch Insulin Syringes are suitable for all home injection and ...
INSUL by AgVa
Noida, India
51-100 Employees
-
Disposables of INSUL by Agva cost less than Rs 500 per month. INSUL by AgVa is the only pump in the market that has a jumbo cartridge with 500 Units capacity to continue non-stop for two weeks. Hence, using of AgVa’s Insulin Pump, disposable sets, and strips, you save Rs. INSUL by AgVa is ideal for elderly people who have multiple comorbidities as it is extremely user friendly and cost-effective. INSUL by AgVa ensures that your busy schedule does not affect your diabetic status. You can carry on with your activities as INSUL is discrete & easy to wear. While you look after your family, INSUL by AgVa looks after you and your health.
Product
INSUL by AgVa (Insulin Pump)
... advanced and affordable Insulin pump. Purchase from the official ...
RayMed
London, United Kingdom
1-10 Employees
2019
RayMed is one of the fastest growing medical supply companies in the UK. Our vision is to supply the entire UK with high quality medical products and set a new standard for the rest of the world. Our mission is to improve the quality of life for everyone, especially those who cannot obtain decent healthcare. We provide a special service for all of our customers, we enjoy dealing with orders of any sizes and can tailor a service just for you. Every day we aim to pursue this goal with energy and commitment, we are determined to achieve this task by delivering the demands of Britain’s healthcare. Warehouse & Distribution: We safely stock, process and dispatch all our products with the highest security using effective stock control and traceability measures. We utilize an efficient custom built warehouse management and stock control system. Products are stored and handled safely according to product instructions set by manufacturers.
Product
Rays InJ/Light 1ml Insulin Syringe
... For sterile insulin syringe click here CE marked and also used by the ...
ShenYang Comeboard Technology Co., Ltd
-
501-1000 Employees
-
We are committed to being the strategic partner that helps you deliver care to build a better, healthier future for our world. We are focused on and have been purpose-built to help you take on today’s healthcare complexities. Supply chain disruptions and product failings can present real threats to the health of your organization. When your supply chain is unreliable or you exper- ience poor product performance, there are measurable costs – both human and financial. Now more than ever, healthcare facilities are faced with mounting pressures to simplify, standardize and increase effi- ciencies in order to improve the overall financial health of the hospital system.
Product
Most popular insulin pen syringe 1ml manufacturer
... Product name Insulin Syringe Material PP Components Barrel+Piston+ ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about your company results for Insulin
| Country with most fitting companies | Netherlands |
| Amount of fitting manufacturers | 1287 |
| Amount of suitable service providers | 1018 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2006 |
| Youngest suiting company | 2021 |
20%
40%
60%
80%
Insulin is a peptide hormone produced by the beta cells of the pancreatic islets; it plays a critical role in the regulation of glucose metabolism. The hormone facilitates the cellular uptake of glucose, thereby lowering blood sugar levels. It achieves this by binding to insulin receptors on the cell surface, which triggers a series of intracellular processes that allow cells to absorb glucose from the bloodstream. Furthermore, insulin aids in fat storage and prevents the breakdown of fat and protein, serving as an anabolic hormone. Its discovery in 1921 by Frederick Banting and Charles Best marked a significant milestone in medical science, transforming type 1 diabetes from a fatal disease to a manageable condition. Insulin's role extends beyond glucose regulation; it also impacts fat and protein metabolism, influencing energy storage and utilization in the body. The hormone's balance is vital; both its deficiency and excess can lead to serious health complications, such as hypoglycemia, hyperglycemia, and diabetic ketoacidosis. Consequently, insulin therapy is a cornerstone in the treatment of diabetes, tailored to mimic natural insulin secretion patterns to maintain blood glucose levels within a normal range. This therapeutic approach has evolved with advancements in biotechnology, leading to the development of various insulin types with different onset and duration of action, enhancing the quality of life for individuals with diabetes.
1. Precise Blood Sugar Control
Insulin offers a level of blood sugar management that is unmatched by oral medications. It mimics the body's natural insulin response more closely, allowing for more accurate adjustments in response to blood sugar levels. This precision is particularly beneficial for individuals with type 1 diabetes, who require external insulin for survival.
2. Reduced Risk of Long-Term Complications
By maintaining closer control over blood sugar levels, insulin helps to minimize the risk of serious diabetes-related complications, such as neuropathy, retinopathy, and kidney disease. Effective management of blood sugar levels can significantly improve the quality of life and reduce healthcare costs over time.
3. Versatility and Flexibility
Insulin therapy can be tailored to fit individual needs and lifestyles. It is available in various formulations that differ in how quickly they start to work and how long their effects last. This flexibility allows for personalized treatment plans that can accommodate different eating habits, activity levels, and schedules, providing a more customized approach to diabetes management.
4. Improved Insulin Sensitivity
Regular insulin use can improve the body's sensitivity to insulin, making it more effective at lowering blood sugar levels. This can be especially important for individuals with type 2 diabetes who have developed insulin resistance, as it can potentially reduce the amount of insulin needed over time.
1. Regulatory Compliance
Ensure the supplier meets all local and international regulations for pharmaceutical manufacturing and distribution, including FDA approval for the U.S. market.
2. Quality Assurance Processes
Verify that the supplier implements rigorous quality control measures at every stage of production to ensure the insulin's purity, potency, and safety.
3. Supply Chain Reliability
Assess the reliability of the supplier's supply chain to ensure consistent availability and timely delivery of insulin, minimizing the risk of shortages.
4. Storage and Handling Practices
Check that the supplier has appropriate storage and handling practices for insulin, as improper conditions can degrade its effectiveness.
5. Cost-effectiveness
Compare prices among suppliers while considering the overall value, including quality, reliability, and additional services offered, to ensure cost-effectiveness.
6. Customer Support and Services
Evaluate the level of customer support provided, including responsiveness, technical assistance, and the availability of educational resources for safe insulin use.
In the pharmaceutical industry, insulin serves as a critical component in the management of diabetes, a condition affecting millions worldwide. Manufacturers and healthcare providers engage in B2B transactions to secure bulk quantities of insulin, ensuring a steady supply for patient treatment plans. This demand drives continuous research and development, fostering partnerships between biotech firms and pharmaceutical companies to innovate more effective and longer-lasting insulin formulations. Another significant B2B use case for insulin is found in the research and development sector. Academic institutions, biotechnology firms, and pharmaceutical companies often purchase insulin in bulk for use in various research projects. These projects may include studying insulin’s effects on cellular processes, developing new insulin delivery methods, or exploring its potential in treating other conditions. Such research initiatives frequently lead to the discovery of new therapeutic applications and improved diabetes management strategies. Furthermore, insulin finds applications in the veterinary medicine industry. Veterinary pharmaceutical companies source insulin to produce treatments for pets, primarily cats and dogs, diagnosed with diabetes. This market niche requires specialized formulations tailored to the metabolic needs of different animal species, presenting opportunities for B2B agreements between insulin manufacturers and veterinary health product companies. Collectively, these use cases underscore insulin's importance not just in diabetes management but also in advancing medical research and catering to the veterinary health sector, demonstrating its versatile applications across various industries.
Insulin, a critical component in the management of diabetes, has reached the highest Technology Readiness Level (TRL) 9, indicating it is fully mature and deployed in operational environments. The journey to this TRL reflects extensive clinical research, development, and refinement over decades. Initially discovered in 1921, insulin’s path to TRL 9 involved the transition from animal-sourced insulins to recombinant DNA technology in the 1980s, which allowed for the mass production of human insulin. This technological leap significantly reduced the immunogenicity associated with animal insulins and improved safety and efficacy for human use. Further advancements led to the creation of insulin analogs with varied time-action profiles, enhancing patient quality of life by offering more flexible dosing schedules that better mimic natural insulin release. The development of delivery systems, such as insulin pens, pumps, and most recently, continuous glucose monitoring (CGM) systems paired with insulin pumps for closed-loop therapy, underscores the technical evolution supporting insulin’s TRL 9 status. These innovations have solidified insulin's role in diabetes management, demonstrating its reliability, safety, and efficacy in real-world settings. The technical reasons anchoring insulin at TRL 9 include its well-established production processes, extensive clinical validation, and the integration of advanced delivery systems that improve therapeutic outcomes.
In the Short-Term, advancements in insulin technology are poised to significantly enhance the ease of diabetes management. Innovations such as faster-acting insulin analogs and smart insulin pens that connect to mobile apps for dose tracking are at the forefront. These developments aim to improve blood sugar control and simplify the monitoring process, making diabetes care more efficient and less intrusive for patients. Looking at the Mid-Term, the focus shifts towards the integration of continuous glucose monitoring (CGM) systems with insulin delivery devices. This period will likely witness the emergence of more sophisticated closed-loop systems, or 'artificial pancreas', which adjust insulin delivery in real-time based on CGM data. This technology promises to minimize the risks of hypo- and hyperglycemia, significantly reducing the daily burden on individuals with diabetes by automating insulin dosing. In the Long-Term, the horizon expands to groundbreaking research on insulin independence. Key efforts include the development of beta cell replacement therapies and immunotherapies that aim to protect or regenerate insulin-producing cells, potentially offering a cure for type 1 diabetes. Additionally, novel drug formulations are being explored to enable oral or inhalable insulin, which could revolutionize the method of insulin administration, making it more convenient and less painful for patients worldwide.
Some interesting questions that has been asked about the results you have just received for Insulin
What are related technologies to Insulin?
Based on our calculations related technologies to Insulin are Aromatics, Desiccants, Refrigerants, Resins, Green Chemistry
Who are Start-Ups in the field of Insulin?
Start-Ups who are working in Insulin are Kaio-Dia Europe
Which industries are mostly working on Insulin?
The most represented industries which are working in Insulin are Healthcare, Other, Medical, IT, Software and Services, Retail
How does ensun find these Insulin Suppliers?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
